Compare Amphastar Pharmaceuticals Inc (AMPH) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Schlumberger NV — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Schlumberger NV trades at $53.6 (market cap $78.96B). The key difference: Schlumberger NV is far larger — about 91.4× Amphastar Pharmaceuticals Inc's market cap, and Schlumberger NV pays a 2.22% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SLB | |
|---|---|---|
Market Cap | $863.95M | $78.96B |
Sector | Health | Energy |
52-Week High | $30.81 | $58.01 |
52-Week Low | $16.87 | $31.72 |
Enterprise Value | $1.26B | $87.68B |
Dividend Yield | — | 2.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
SLB's stock trades at $50.53, down 1.96% over the past day, but maintains a bullish technical signal with strong moving average support. The company recently reported Q2 2026 earnings of $0.55 per share, beating estimates, and has a consensus analyst price target of $63.00. Revenue for 2025 was $35.71 billion, with a net income margin of 8.53% and a P/E ratio of 24.65.
The outlook for SLB is positive, driven by growth in offshore, digital, and production segments, though risks include Middle East volatility and net debt levels. With 85% of analysts rating it a buy and a dividend yield supported by recent payments, the stock presents a compelling opportunity for investors seeking energy sector exposure with solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
